Psychological & Neuropsychological Test

Similar documents
Residential Treatment (RTC)

Inpatient Mental Health

Applied Behavior Analysis Therapy for Treatment of Autism Spectrum Disorder

Applied Behavior Analysis Therapy for Treatment of Autism Spectrum Disorder

No An act relating to health insurance coverage for early childhood developmental disorders, including autism spectrum disorders. (S.

TESTING GUIDELINES PerformCare: HealthChoices. Guidelines for Psychological Testing

Physical Therapy MM /15/2003

MEDICAL POLICY No R4 NEUROPSYCHOLOGICAL AND PSYCHOLOGICAL TESTING

Positive Airway Pressure and Oral Devices for the Treatment of Obstructive Sleep Apnea

Polysomnography and Sleep Studies

Admission Criteria Continued Stay Criteria Discharge Criteria. All of the following must be met: 1. Member continues to meet all admission criteria

Applied Behavior Analysis for Autism Spectrum Disorders

Insulin Pumps - External

Positive Airway Pressure and Oral Devices for the Treatment of Obstructive Sleep Apnea

Negative Pressure Wound Therapy (NPWT)

Neuropsychological Testing (NPT)

Lung-Volume Reduction Surgery ARCHIVED

Oxygen and Oxygen Equipment

Continuous Glucose Monitoring System

Continuous Glucose Monitoring System

Posterior Tibial Nerve Stimulation

Low-Molecular-Weight Heparin

MEDICAL POLICY MEDICAL POLICY DETAILS POLICY STATEMENT POLICY GUIDELINES. Page: 1 of 5

Continuous Glucose Monitoring System

Extracorporeal Membrane Oxygenation (ECMO)

Growth Hormone Therapy

Oxygen and Oxygen Equipment

Home Total Parenteral Nutrition for Adults

MEDICAL POLICY SUBJECT: PSYCHOLOGICAL TESTING. POLICY NUMBER: CATEGORY: Behavioral Health

Bariatric Surgery MM /11/2001. HMO; PPO; QUEST 05/01/2012 Section: Surgery Place(s) of Service: Outpatient; Inpatient

MEDICAL POLICY SUBJECT: APPLIED BEHAVIOR ANALYSIS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDERS

Clinical Policy: Olanzapine Orally Disintegrating Tablet (Zyprexa Zydis) Reference Number: CP.PMN.29 Effective Date: Last Review Date: 02.

ADMINISTRATIVE POLICY AND PROCEDURE

Prophylactic Mastectomy

Extracorporeal Membrane Oxygenation (ECMO)

Evaluating Elements of Scopes of Practice in the Military Health System

Empire BlueCross BlueShield Professional Commercial Reimbursement Policy

INTERQUAL BEHAVIORAL HEALTH CRITERIA ADOLESCENT PSYCHIATRY REVIEW PROCESS

See Important Reminder at the end of this policy for important regulatory and legal information.

Intensity Modulated Radiation Therapy (IMRT)

INTERQUAL BEHAVIORAL HEALTH CRITERIA GERIATRIC PSYCHIATRY REVIEW PROCESS

BEHAVIOR ANALYSIS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDERS

MEDICAL POLICY SUBJECT: APPLIED BEHAVIOR ANALYSIS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDERS

Medical Necessity Guidelines: Applied Behavioral Analysis (ABA) including Early Intervention for RITogether

MEDICAL POLICY Children's Intensive Behavioral Service/ Applied Behavioral Analysis (ABA)

Occupational Therapy. Occupational Therapy Payment Policy Page 1

Clinical Policy: Rivastigmine (Exelon) Reference Number: CP.PMN.101 Effective Date: Last Review Date: 02.18

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Clozapine orally disintegrating tablet (Fazaclo) Reference Number: CP.PMN.12 Effective Date: Last Review Date: 02.

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Naltrexone (Vivitrol) Reference Number: CP.PHAR.96 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Naltrexone (Vivitrol) Reference Number: CP.PHAR.96 Effective Date: Last Review Date: Line of Business: Medicaid

Velcade (bortezomib)

Incontinence Supplies

Somatuline Depot (lanreotide)

Artificial Disc Replacement, Cervical

Clinical Policy: Levetiracetam (Spritam) Reference Number: CP.CPA.156 Effective Date: Last Review Date: 11.18

Clinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.18

It is the policy of health plans affiliated with Centene Corporation that Seroquel XR is medically necessary when the following criteria are met:

Polysomnography - Sleep Studies

See Important Reminder at the end of this policy for important regulatory and legal information.

Approved by: Integrated Health Quality Management Subcommittee Effective Date: Department of Origin: Integrated Healthcare Services.

Clinical Policy: Dabrafenib (Tafinlar) Reference Number: CP.PHAR.239 Effective Date: 07/16 Last Review Date: 07/17 Line of Business: Medicaid

Clinical Policy: Multiple Sleep Latency Testing

NEUROPSYCHOLOGY SERVICE

ACUTE INPATIENT TREATMENT

See Important Reminder at the end of this policy for important regulatory and legal information.

ADMINISTRATIVE POLICY AND PROCEDURE

See Important Reminder at the end of this policy for important regulatory and legal information.

Velcade (bortezomib)

Clinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.19

Photochemotherapy MM /09/2004. HMO; PPO; QUEST Integration June 1, 2016 Section: Medicine Place(s) of Service: Home; Office

Erythropoiesis Stimulating Agents (ESA)

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy

See Important Reminder at the end of this policy for important regulatory and legal information.

Bevacizumab (Avastin)

Clinical Policy: Buprenorphine-Naloxone (Bunavail, Suboxone, Zubsolv) Reference Number: CP.PMN.81 Effective Date: Last Review Date: 02.

Torisel (temsirolimus)

Intensity Modulated Radiation Therapy (IMRT)

Remicade (Infliximab)

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: EEG in the Evaluation of Headache Reference Number: CP.MP.155

Clinical Policy: Lisdexamfetamine (Vyvanse) Reference Number: CP. PPA.03. Line of Business: Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

Speech Therapy. 4. Therapy is used to achieve significant, functional improvement through specific diagnosisrelated

Clinical Policy: Lisdexamfetamine (Vyvanse) Reference Number: CP.PMN.121 Effective Date: Last Review Date: Line of Business: Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

16 SB 319/AP. Senate Bill 319 By: Senators Jackson of the 2nd, Kirk of the 13th, Unterman of the 45th, Henson of the 41st and Orrock of the 36 th

CT Behavioral Health Partnership. Autism Spectrum Disorder (ASD) Level of Care Guidelines

See Important Reminder at the end of this policy for important regulatory and legal information.

Florida Medicaid. Dental Services Coverage Policy. Agency for Health Care Administration

Clinical Policy: Levomilnacipran (Fetzima) Reference Number: HIM.PA.125 Effective Date: Last Review Date: 11.18

See Important Reminder at the end of this policy for important regulatory and legal information.

Photochemotherapy MM /09/2004. HMO; PPO; QUEST Integration 08/25/2017 Section: Medicine Place(s) of Service: Home; Office

03/14/17. II. Initial early intensive-level behavioral and developmental therapy must have both of the following: A and B

See Important Reminder at the end of this policy for important regulatory and legal information.

Transcription:

An Independent Licensee of the Blue Cross and Blue Shield Association Psychological & Neuropsychological Test BEACON HEALTH STRATEGIES, LLC ORIGINAL EFFECTIVE DATE HAWAII LEVEL OF CARE CRITERIA 2013 CURRENT EFFECTIVE DATE 11/1/2017 I. Description Psychological and neuropsychological testing is the use of standardized assessment tools to gather information relevant to a member s intellectual, cognitive, and psychological functioning. Psychological testing can be used to determine differential diagnosis and assess overall psychological and neuropsychological functioning. Test results may have important implications for diagnosis and treatment planning. A licensed psychologist performs psychological testing, either in independent practice as a health services provider, or in a clinical setting. Psychology doctoral candidates may test members and interpret test results; provided the evaluation is conducted in a clinical setting, and that the testing is directly supervised and co-signed by a qualified licensed psychologist. Psychology assistants may not test members under the supervision of a psychologist in an independent practice setting. Neuropsychological testing is most often utilized for members with cognitive impairments that impede functioning on a day to day basis. All testing is subject to the admission and criteria below, however the following guidelines are most common testing issues: Testing is approved only for licensed psychologists and other clinicians for whom testing falls within the scope of their clinical license and have specialized training in psychological and/or neuropsychological testing. Educational testing is not a covered benefit, though this may be subject to state and accountspecific arrangements. Assessment of possible learning disorder or developmental disorders is provided by school system per federal mandate PL 94-142 When neuropsychological testing is requested secondary to a clear, documented neurological injury or other medical/neurological condition (i.e. Stroke, traumatic brain injury multiple sclerosis), this may be referred to the medical health plan, though this determination may be subject to state and account-specific guidelines. Neurology consult may be required prior to request. All tasks involving projective testing must be performed by a licensed psychologist or other licensed clinician with specialized training in projective testing and who is permitted by state licensure. The expectation is that diagnosis of ADHD can be made by a psychiatric consult and may not require psychological testing. Testing requested by the legal or school system is not generally a covered benefit, unless specified by state regulations or account-specific arrangements

2 II. Criteria/Guidelines A. Admission Criteria The following criteria must apply: Psychological Testing 1-3 must be met: 1. Request for testing is based on need for at least one of the following: a. Differential diagnosis of mental health condition unable to be completed by traditional assessment; b. Diagnostic clarification due to a recent change in mental status for appropriate level of care determination / treatment needs due to lack of standard treatment response. 2. Repeat testing needed as indicated by ALL of the following a. Proposed repeat psychological testing can help answer question that medical, neurologic, or psychiatric evaluation, diagnostic testing, observation in therapy, or other assessment cannot. b. Results of proposed testing are judged to be likely to affect care or treatment of member (i.e. contribute substantially to decision of need for or modification to a rehabilitation or treatment plan). c. Member is able to participate as needed such that proposed testing is likely to be feasible (i.e. appropriate mental status, intellectual abilities, language skills). d. No active substance use, withdrawal, or recovery from recent chronic use and e. Clinical situation appropriate for repeat testing as indicated by 1 or more of the following: i. Clinically significant change in member's status (i.e., worsening or new symptoms or findings) ii. Other need for interval reassessment that will inform treatment plan 3. The member must have: a. Diagnostic evaluation (including psychosocial functioning), unless subject to state regulation or account-specific arrangements. b. No active withdrawal and/or substance misuse within 2 months of request 4. The member is experiencing cognitive impairments; B. Criteria for Tests 1. Tests must be published, valid, and in general use as evidenced by their presence in the current edition of Tests in Print IX, or by their conformity to the Standards for Educational and Psychological Tests of the American Psychological Association.

3 2. Tests are administered individually and are tailored to the specific diagnostic questions of concern. III. Limitations/Exclusions A. Non-Reimbursable Tests: 1. Self-rating forms and other paper and pencil instruments, unless administered as part of a comprehensive battery of tests, (e.g., MMPI or PIC) as a general rule. 2. Group forms of intelligence tests. 3. Short form, abbreviated, or quick intelligence tests administered at the same time as the Wechsler or Stanford-Binet tests. 4. A repetition of any psychological test or tests provided to the same member within the preceding six months, unless documented that the purpose of the repeated testing is to ascertain changes: a. Following such special forms of treatment or intervention such as ECT; b. Relating to suicidal, homicidal, toxic, traumatic, or neurological conditions. 5. Tests for adults that fall in the educational arena or in the domain of learning disabilities. 6. Testing that is mandated by the courts, Department of Children s Services or other social/legal agency in the absence of a clear clinical rationale. Please Note: Beacon will not authorize periodic testing to measure the member s response to psychotherapy. B. Services that are not covered [Exclusions]: Any of the following criteria are sufficient for exclusion from this level of care: 1. Testing is primarily to guide the titration of medication. 2. Testing is primarily for legal purposes, unless specified by state regulations or account-specific arrangements. 3. Testing is primarily for medical guidance, cognitive rehabilitation, or vocational guidance, as opposed to the admission criteria purposes stated above. 4. Testing request appears more routine than medically necessary (i.e. a standard test battery administered to all new members). 5. Interpretation and supervision of neuropsychological testing (excluding the administration of tests) is performed by someone other than a licensed psychologist or other clinician whom neuropsychological testing falls within the scope of their clinical license, and who has had special training in neuropsychological testing. 6. Measures proposed have no standardized norms or documented validity. 7. The time requested for a test/test battery falls outside Beacon Health Options established time parameters.

4 8. Extended testing for ADHD has been requested prior to provision of a thorough evaluation, which has included a developmental history of symptoms and administration of rating scales. 9. Symptoms of acute psychosis, confusion, disorientation, etc., interfering with proposed testing validity are present. 10. Administration, scoring and/or reporting of projective testing is performed by someone other than a licensed psychologist, or other clinician for whom psychological testing falls within the scope of their clinical licensure and who has specialized training in psychological testing. IV. Administrative Guidelines A. Precertification is not required. HMSA and Beacon reserves the right to perform retrospective review using the above criteria to validate if service rendered met payment determination criteria. B. Applicable codes: V. Important Reminder Psychological Testing Neuropsychological Testing 96101 96118 96102 96119 96103 96120 The purpose of this Medical Policy is to provide a guide to coverage. This Medical Policy is not intended to dictate to providers how to practice medicine. Nothing in this Medical Policy is intended to discourage or prohibit providing other medical advice or treatment deemed appropriate by the treating physician. Benefit determinations are subject to applicable member contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. This Medical Policy has been developed through consideration of the medical necessity criteria under Hawaii s Patients Bill of Rights and Responsibilities Act (Hawaii Revised Statutes 432E-1.4), generally accepted standards of medical practice and review of medical literature and government approval status. HMSA has determined that services not covered under this Medical Policy will not be medically necessary under Hawaii law in most cases. If a treating physician disagrees with HMSA s determination as to medical necessity in a given case, the physician may request that HMSA reconsider the application of the medical necessity criteria to the case at issue in light of any supporting documentation.

5 Beacon uses its LOC criteria as guidelines, not absolute standards, and considers them in conjunction with other indications of a member s needs, strengths, and treatment history in determining the best placement for a member. Beacon s LOC criteria are applied to determine appropriate care for all members. In general, members will only be certified if they meet the specific medical necessity criteria for a particular LOC. However, the individual s needs and characteristics of the local service delivery system are taken into consideration. In addition to meeting Level of Care Criteria; services must be included in the member s benefit to be considered for coverage. VI. References 1. MCG Health Behavioral Health Care 21st Edition Copyright 2017 MCG Health, LLC a. American Academy of Clinical Neuropsychology. American Academy of Clinical Neuropsychology (AACN) practice guidelines for neuropsychological assessment and consultation. Clinical Neuropsychologist 2007;21(2):209-31. DOI: 10.1080/13825580601025932. (Reaffirmed 2016 Sep) b. Carlson JF, Geisinger KF, Jonson JL. The Nineteenth Mental Measurements Yearbook Lincoln, NE: University of Nebraska Press 2014. c. Anderson N, Schlueter JE, Carlson JF, Geisinger KF. Tests in Print IX an index to tests, test reviews, and the literature on specific tests. Lincoln, NE: University of Nebraska Press 2016. d. Neurodevelopmental disorders. In: American Psychiatric Association, editor. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013:31-86. e. Meyer GJ, et al. Psychological testing and psychological assessment. A review of evidence and issues. American Psychologist 2001;56(2):128-65. f. Palumbo D, Lynch PA. Psychological testing in adolescent medicine. Adolescent Medicine Clinics 2006;17(1):147-64. DOI: 10.1016/j.admecli.2005.10.003. g. Swanda RM, Haalanda KV. Clinical neuropsychology and intellectual assessment of adults. In: Sadock BJ, Sadock VA, Ruiz P, editors. Kaplan & Sadock's Comprehensive Textbook of Psychiatry. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2009:935-51 h. McDermott BE. Psychological testing and the assessment of malingering. Psychiatric Clinics of North America 2012;35(4):855-76. DOI: 10.1016/j.psc.2012.08.006. 2. http://www.psychiatryonline.com/pracguide/pracguidetopic_7.aspx. VII. Related Policies A. CSNT 123.1 Minimum Program Standards by Level of Care B. CUR 152 Application of Level of Care Criteria and Authorization Procedures -Commercial C. CUR 153 Application of Level of Care Criteria and Authorization Procedures - Medicaid